23-392 Phase I
A Phase 1a/1b, Dose-Escalation/Dose-Expansion study of NPX267 in Subjects with Solid Tumors Known to Express HHLA-2
A Phase 1a/1b, Dose-Escalation/Dose-Expansion study of NPX267 in Subjects with Solid Tumors Known to Express HHLA-2
An Open-Label Study of GV20-0251 in Patients with Advanced and/or Refractory Solid Tumor Malignancies
An Open-Label, Multicenter Study of LOXO-435 (LY3866288) in Advanced Solid Tumor Malignancies with FGFR3 Alterations
Bladder fiducial markers and multiparametric-MRI (mp-MRI) to optimize bladder chemo-radiotherapy
Phase 1/2 Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants with Advanced Solid Tumors
Sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma progressing on platinum-based chemotherapy and PD1/L1 inhibitors: the Double Antibody Drug conjugate (DAD) Phase I trial